VEGF signaling inhibitors: more pro-apoptotic than anti-angiogenic

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The vascular endothelial growth factor (VEGF) family and its receptors (VEGFRs) regulate critical cellular processes.
• While angiogenesis is a well-known VEGF-mediated effect, other actions include increased vascular permeability, growth factor release, cell motility, and apoptosis inhibition.

Purpose of the Study:

• To explore the mechanisms behind anti-VEGF therapy's chemosensitizing effects.
• To investigate the role of tumoral VEGFRs in anti-VEGF drug action.

Main Methods:

• The study reviews existing literature and clinical observations on VEGF, VEGFRs, and anti-VEGF therapies.
• It analyzes the downstream effects of VEGF signaling and the clinical outcomes of bevacizumab treatment.

Main Results:

• Contrary to theoretical expectations, anti-VEGF therapy (bevacizumab) acts as a broad-spectrum chemosensitizer.
• This chemosensitization is better explained by direct inhibition of tumor cell survival signals via tumoral VEGFRs, rather than indirect vascular effects.

Conclusions:

• The emerging model suggests that anti-VEGF drugs primarily act on tumoral VEGFRs.
• This understanding has significant implications for optimizing anti-metastatic efficacy and developing new therapeutic strategies targeting the VEGF pathway.